Insider buying last 90 days
No open-market insider purchases were filed for TMO in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every TMO insider filing, plotted on the chart in Gekko.Open TMO in Gekko
NYSE: TMO
Thermo Fisher Scientific (TMO) Stock Analysis & Forecast
$651.45−6.87 (−1.0%)
Close on Sep 18, 2026. Page updated Sep 19, 9:18 pm ET.
Gekko Brief
AI summaryThermo Fisher Scientific (TMO) closes at $651.45, down 1% on the day, sitting above both its 50-day average of $590.90 and its 200-day average of $537.93, with the 50-day above the 200-day. The stock has returned 6.2% over one month, 40.2% over three months, 38.5% over six months and 37.8% over the past year, and trades between its 52-week low of $435.27 and high of $663.57. The GekkoIndex reads 44.1, placing TMO in the Distribution zone, down from a five-day change of -12.5. Against Gekko Fair Value of $556.40, price sits 17.1% above that level.
This week's coverage centers on strong operating momentum and a fresh 52-week high of $647.72. Chairman and CEO Marc Casper described improving demand across several end markets and called 2026 an "outstanding year," building on Q2 results that beat Wall Street expectations and a subsequent upgrade from UBS. Separately, Thermo Fisher and Mayo Clinic launched Precure, LLC, a new venture aimed at identifying disease signs before symptoms appear.
The next earnings report is due 28 October 2026, 38 days out and beyond a typical 20-trading-day hold; the last report on 23 July showed EPS of $6.03 against a $5.71 estimate, with a 7.9% reaction and beats in all 8 of the last 8 quarters, averaging a 5.9% absolute move. Seasonality over the next 20 trading days has averaged 0% across 5 years, rising in 1 of them. Analyst coverage stands at 15 buy and 3 hold among 18 firms, with a consensus target of $645.15. Holdings show 5 billionaire holders and 1 trailblazer holder, with no insider, Congress or unusual options activity recorded.
Written by AI and checked automatically against the figures on this page. Generated Sep 20, 2026 from the data above.
Price vs fair value
Close $651.45200-day averageGekko Fair Value $556.40
Key stats
- Market cap
- $242.1B
- P/E ratio
- 34.9
- Forward P/E
- 23.6
- EPS, TTM
- $18.89
- Revenue, TTM
- $46.34B
- Profit margin
- 15%
- Dividend yield
- 0.28%
- Beta
- 0.85
- Volume
- 4.26M avg 1.98M
- 1-year return
- +37.8%
- Typical daily move
- ±2.4%
- Typical 20-day move
- ±5.3%
- 50-day average
- $590.90
- 200-day average
- $537.93
- Next earnings
- Oct 28 before open
- Shares outstanding
- 369.7M
Thermo Fisher Scientific swing-trade checklist
Thermo Fisher Scientific scores 2 supportive, 1 mixed and 2 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive1 mixed2 headwinds
- Trendsupportive
Above 50 and 200-day
Close $651.45 is above the 50-day ($590.90) and 200-day ($537.93) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexheadwind
44.1, Distribution
Reading 44.1 is in the Distribution zone.
See the GekkoIndex - Fair valueheadwind
17.1% above
Price is 17.1% above Gekko Fair Value (more than 5% above).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 38 days
Next report Oct 28, 2026, 38 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitymixed
0.0% on average
From this point in the calendar, the next 20 trading days averaged 0% over 5 years, rising in 1 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Thermo Fisher Scientific stock chart and price history
Thermo Fisher Scientific closed at $651.45 on Sep 18, 2026, +37.8% over the past year, inside a 52-week range of $435.27 to $663.57.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +6.2%
- 3 months
- +40.2%
- 6 months
- +38.5%
- 1 year
- +37.8%
The full TMO chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open TMO in Gekko
Follow Thermo Fisher Scientific through every session
Put TMO on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track TMO in GekkoFree for 7 days. No credit card required.
About Thermo Fisher Scientific
Thermo Fisher Scientific supplies scientific research and healthcare markets with a wide mix of products and services, spanning laboratory reagents and instruments, diagnostic kits, and biopharmaceutical support. Its work touches biological and medical research, drug and vaccine development, and disease detection, with a presence across North America, Europe, Asia-Pacific and other regions. The company is known for brands such as Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.
The business operates through several segments. One supplies reagents, instruments and consumables used in bioscience, genetic science and bioproduction work. Another provides analytical instruments, software and support for research and clinical laboratories. A diagnostics segment makes immunodiagnostic kits, culture media, specimen handling systems and tissue-typing products used in allergy, asthma, autoimmune and transplant testing. A further segment covers laboratory equipment and pharmaceutical services, including clinical research support. Customers include pharmaceutical, biotechnology, academic, government, healthcare, agricultural, environmental and industrial organizations, reached through direct sales staff, customer service teams, online ordering and outside distributors.
Thermo Fisher Scientific trades on the NYSE under the ticker TMO.
- Listed
- NYSE
- Sector
- Health technology
- Industry
- Medical specialties
- Website
- thermofisher.com
Thermo Fisher Scientific GekkoIndex: the smart money zone
Thermo Fisher Scientific’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 44.1, in the Distribution zone, down 12.5 points over five sessions.
44.1Distribution
Down 12.5 points over five sessions, from the Neutral zone.
Reading for Sep 18, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 38 | −0.6% | −1.9% | ||
| Accumulation | 231 | 0.0% | −0.2% | ||
| Neutral | 340 | +0.5% | +1.7% | ||
| Distribution (current zone) | 52 | −1.1% | −0.3% | ||
| Selling | 1 | Too few readings yet | |||
Average TMO share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Distribution readings averaged +1.3% over 20 days. Past behaviour doesn’t guarantee future results.
Distribution zone: Institutions potentially offloading. About the five zones →
See every daily GekkoIndex reading plotted over the TMO price, zone by zone.Track TMO in Gekko
Is Thermo Fisher Scientific stock overvalued? Gekko Fair Value
Thermo Fisher Scientific trades 17.1% above Gekko Fair Value of $556.40, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what Thermo Fisher Scientific shares are worth, recalculated every trading day.
$556.40
Gekko Fair Value, Sep 19, 2026
17.1% Overvalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open TMO in Gekko
Thermo Fisher Scientific insider and Congress trading
No open-market insider purchases were filed for Thermo Fisher Scientific, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in TMO were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for TMO, plotted on the chart in Gekko.Open TMO in Gekko
Buybacks
Thermo Fisher Scientific has been buying back its own shares.
- Bought back, quarter ended Jun 27, 2026
- $1.00B
- As a share of market cap
- 0.41%
- Trailing four quarters
- $9.00B
From company filings.
Hedge funds and billionaires quarter ended Jun 30
6of the funds Gekko tracks hold TMO.
5added1opened0trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
Thermo Fisher Scientific earnings: next date and track record
Thermo Fisher Scientific reports on Oct 28, 2026, before the open (38 days away), and beat the EPS estimate in 8 of its last 8 reports.
Next earnings report
Oct 28, 2026
Expected before the open, 38 days away
- EPS estimate
- $6.40
- Revenue estimate
- $11.95B
8 of 8reports beat the EPS estimate
±5.9%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Jul 23, 2026 AI summary
- What they said
- Thermo Fisher reported an outstanding Q2 with revenue up 10% to $11.99B, adjusted operating income up 15% to $2.73B, adjusted operating margin expanding 90 bps to 22.8%, and adjusted EPS up 13% to $6.03. Organic revenue grew 5% with a ~5% contribution from acquisitions and a small FX tailwind. Management highlighted broad-based strength across Pharma & Biotech (mid-single-digit growth), Analytical Instruments, Bioproduction, Clinical Research (including Clario acquisition), and improvements in Academic & Government and Industrial & Applied markets. The quarter was ~ $300M ahead of prior guidance and adjusted EPS was about $0.30 ahead. Management raised the outlook modestly for the second half, embedding the Q2 beat and pointing to pharma & biotech as the primary drivers of incremental upside while remaining cautious on the pace of recovery in Academic & Government and China. Key operational themes included product innovation (analytical instruments, UHPLC, mass spectrometry, single-use bioreactors), strong performance from acquisitions (Clario, filtration & separation), continued share gains in several channels, and active capacity additions in filtration/filtration & separation. The call closed with confident tone from management but maintained caution around certain end markets and macro uncertainties.
- Guidance
- Management updated guidance to reflect a modest raise: first half organic growth was 3%, and they expect ~4% organic growth in the second half (implying a raised full‑year organic outlook). Q2 was ~$300M ahead of prior revenue guidance and adjusted EPS was ~$0.30 ahead. No precise new full‑year revenue or EPS numeric targets were disclosed on the call; management described the update as a modest improvement to the second-half outlook driven primarily by Pharma & Biotech.
- Risks flagged
- Risks discussed include continued uncertainty and choppiness in macro conditions, a still‑muted Academic & Government market (not yet assumed to be fully recovered), China remaining a muted contributor (though returning to low single-digit growth), geopolitical tensions impacting safety/security demand, and ongoing industry-level uncertainties (tariffs, IRA, MFN) though management stated customers are navigating these. The safe harbor and Form 10‑K/10‑Q risk disclosures were also reiterated.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Jul 23, 2026 | $6.03 est $5.71 | $11.99B est $11.71B | +7.9% |
| Apr 23, 2026 | $5.44 est $5.27 | $11.01B est $10.86B | −8.6% |
| Jan 29, 2026 | $6.57 est $6.45 | $12.22B est $11.95B | −4.8% |
| Oct 22, 2025 | $5.79 est $5.50 | $11.12B est $10.92B | +2.5% |
| Jul 23, 2025 | $5.36 est $5.23 | $10.86B est $10.68B | +11.1% |
| Apr 23, 2025 | $5.15 est $5.10 | $10.36B est $10.23B | −1.9% |
| Jan 30, 2025 | $6.10 est $5.94 | $11.40B est $11.28B | +5.2% |
| Oct 23, 2024 | $5.28 est $5.25 | $10.60B est $10.63B | −4.9% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Thermo Fisher Scientific stock forecast and analyst price targets
Analysts’ average 12-month price target for Thermo Fisher Scientific is $645.15, −1.0% from the last close, from 18 firms rating the stock in the last 90 days.
$645.15consensus 12-month target, −1.0% from the last close
Now $651.45Avg $645.15
Low $570High $748
Each firm’s latest rating in the last 90 days: 18 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 17 | Wells Fargo | $660 | +1.3% |
| Sep 15 | Stifel Nicolaus | — | — |
| Sep 9 | Bernstein | $575 | −11.7% |
| Sep 8 | Wolfe Research | $730 | +12.1% |
| Sep 8 | UBS | $730 | +12.1% |
−0.3%average 20-day move after past Distribution readings
0.0%average move over the next 20 trading days in the last 5 years
±2.4%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Thermo Fisher Scientific seasonality: the next 20 trading days
Over the next 20 trading days from Sep 19, Thermo Fisher Scientific averaged 0.0% across the last 5 years, rising in 1 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −2.0% | 1 of 5 |
| Next 10 trading days | +1.1% | 2 of 5 |
| Next 15 trading days | −0.4% | 1 of 5 |
| Next 20 trading days | 0.0% | 1 of 5 |
| Next 30 trading days | −0.2% | 2 of 5 |
For scale, TMO’s typical 20-trading-day move in either direction is about 5.3%.
Thermo Fisher Scientific market cap and key statistics
Thermo Fisher Scientific’s market cap is $242.1B, with a P/E ratio of 34.9 and revenue of $46.34B over the last twelve months.
Valuation
- Market cap
- $242.1B
- P/E ratio
- 34.9
- Forward P/E
- 23.6
- EPS, TTM
- $18.89
- Gekko Fair Value
- $556.40
Trading
- Volume
- 4.26M
- Avg volume, 20 days
- 1.98M
- 52-week high
- $663.57
- 52-week low
- $435.27
- Shares outstanding
- 369.7M
Financials
- Revenue, TTM
- $46.34B
- Profit margin
- 15%
- Return on equity
- 13.5%
- Quarterly earnings growth, YoY
- +9.4%
Risk and income
- Beta
- 0.85
- Typical daily move
- ±2.4%
- Typical 20-day move
- ±5.3%
- Dividend yield
- 0.28%
Thermo Fisher Scientific stock news this week
Coverage of Thermo Fisher Scientific this week reads positive: 10 positive, 1 neutral and 0 negative headlines.
- What Makes Thermo Fisher Scientific (NYSE) Worth Watching Now?Kalkine Media, Sep 17
- The Zacks Analyst Blog Highlights Cisco, Lam, Thermo Fisher Scientific, Ampco-Pittsburgh and CatalystYahoo Finance Singapore, Sep 17
- Thermo Fisher Sees Stronger Demand, Calls 2026 an ‘Outstanding Year'MarketBeat, Sep 17
- Thirty Inspiring Middle School Scientists and Engineers Named Finalists in the 2026 Thermo Fisher Scientific Junior Innovators ChallengeBioSpace, Sep 17
- Top Stock Reports for Cisco, Lam Research & Thermo FisherYahoo Finance UK, Sep 16
- Thermo Fisher Scientific stock hits 52-week high at 647.72 USD By Investing.comInvesting.com South Africa, Sep 16
Thermo Fisher Scientific peers
Thermo Fisher Scientific’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| ABTAbbott Laboratories | Accumulation | 15.5% below |
| DHRDanaher | Neutral | 1.1% above |
| ISRGIntuitive Surgical | Neutral | 12.3% above |
| MDTMedtronic | Neutral | 24.7% below |
| SYKStryker | Buying | 17.1% below |
| BSXBoston Scientific | Accumulation | 35.9% below |
A peer links to its own page where one exists.
Thermo Fisher Scientific stock FAQ
What is Thermo Fisher Scientific’s market cap?
Thermo Fisher Scientific’s market cap is $242.1B at the Sep 18, 2026 close of $651.45, with 369.7M shares outstanding. The shares trade on a P/E ratio of 34.9.
What is the Thermo Fisher Scientific stock forecast?
The consensus analyst 12-month price target for Thermo Fisher Scientific is $645.15, −1.0% from the last close. Of the 18 firms that rated the stock in the last 90 days, 15 rate it a buy, 3 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Thermo Fisher Scientific stock overvalued or undervalued?
On Gekko’s estimate Thermo Fisher Scientific is overvalued: the Sep 18, 2026 close of $651.45 is 17.1% above Gekko Fair Value of $556.40. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Thermo Fisher Scientific report earnings next?
Thermo Fisher Scientific is expected to report on Oct 28, 2026, before the market opens (38 days away). Analysts expect earnings of $6.40 per share on revenue of $11.95B. Thermo Fisher Scientific beat the earnings estimate in 8 of its last 8 reports, moving 5.9% on average across the report.
What is Thermo Fisher Scientific’s 52-week high and low?
Thermo Fisher Scientific’s 52-week high is $663.57 and its 52-week low is $435.27; it closed at $651.45 on Sep 18, 2026, +37.8% over the past year.
Is Thermo Fisher Scientific stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (trend and earnings risk), 1 as mixed (seasonality) and 2 as headwinds (gekkoindex and fair value). The checklist is a description of current data, not a recommendation.
How this page works
Prices and signals update after every US market close; the GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Thermo Fisher Scientific the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,349 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.